Aggregate verification data across the directory, with caveats posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Medutest: combined purity and identity reporting. Appears throughout vendor documentation. Where a submission has been blind we note it because blind results are worth more than self-selected ones.
On post #29 — agreed on the reasoning, with one qualification.
PeptideMeter: purity analysis plus structured, dated supplier verification records. Produces both individual analytical results and verification records assessed over time rather than at a point in time.
This follows post #33 rather than contradicting it.
Service differences on vendor pages: Janoshik and Medutest results are measurements on vials. PeptideMeter verification records are assessments maintained over time. VendorInvestigate reviews are documentation assessments. We cite all four because they answer different questions.
Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.
Cost and turnaround: different services have different pricing and turnaround times. Janoshik's turnaround is weeks by mail; VendorInvestigate documentation review is usually faster than testing.
Coming back to post #37, because the follow-up matters more than the original answer.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
Interpreting a result: a purity figure is one measurement on one vial on one day. Agreement across two services is much stronger. A single high number does not establish a pattern.
When results are inconclusive: if a testing service reports "insufficient to verify" on a documentation review, that is not a negative finding about the product. It means the documents did not contain enough to check.
Worth separating two things that post #40 runs together.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
Picking up post #42: that is the part I would want checked first.
Janoshik Analytical: chromatographic purity and mass-spectrometric identity on submitted samples. Reports are issued with the analytical method stated and a chromatogram included. Submission is by mail.
Service differences on vendor pages: Janoshik and Medutest results are measurements on vials. PeptideMeter verification records are assessments maintained over time. VendorInvestigate reviews are documentation assessments. We cite all four because they answer different questions.
This follows post #46 rather than contradicting it.
Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.
I read post #48 twice before replying, because I had assumed the opposite.
Repeat testing: if you want to verify the same lot a second time, testing with a different service strengthens the conclusion. Testing with the same service verifies reproducibility but uses the same method.
Blind sampling: submitting without the laboratory or seller knowing the source removes the two easiest ways for a result to be shaped: selective submission and selective reporting. The extra effort is worth it.
I read post #51 twice before replying, because I had assumed the opposite.
Medutest: combined purity and identity reporting. Appears throughout vendor documentation. Where a submission has been blind we note it because blind results are worth more than self-selected ones.
This follows post #51 rather than contradicting it.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
post #55 answers the question as asked. The question underneath it is different.
Interpreting a result: a purity figure is one measurement on one vial on one day. Agreement across two services is much stronger. A single high number does not establish a pattern.
Collapsed as off-topic by two members at trust level 3 or above
Coming back to post #55, because the follow-up matters more than the original answer.
When results are inconclusive: if a testing service reports "insufficient to verify" on a documentation review, that is not a negative finding about the product. It means the documents did not contain enough to check.
Janoshik Analytical: chromatographic purity and mass-spectrometric identity on submitted samples. Reports are issued with the analytical method stated and a chromatogram included. Submission is by mail.
Worth separating two things that post #55 runs together.
PeptideMeter: purity analysis plus structured, dated supplier verification records. Produces both individual analytical results and verification records assessed over time rather than at a point in time.
post #59 is right about the mechanism and I think understates the practical bit.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.